AbbVie reports third-quarter revenue growth and raises 2026 adjusted EPS guidance

AbbVie lifts its 2026 outlook

AbbVie raised its full-year 2026 adjusted diluted EPS guidance range to $13.95-$13.99 from $13.76-$13.96, citing what it described as a strong outlook and significant momentum. The updated guidance includes an unfavorable $0.69-per-share impact from acquired in-process research and development and milestones expense incurred year to date through the third quarter.

The company also announced a 5.2% increase in its dividend beginning with the payment due in February 2027. These are forward-looking company measures and commitments rather than third-quarter realized results.

Third-quarter revenue and earnings

For the quarter ended September 30, 2026, AbbVie reported worldwide net revenue of $17.404 billion, up 10.3% on a reported basis and 10.5% on an operational basis. GAAP diluted EPS was $2.37, while adjusted diluted EPS was $3.82; both increased by more than 100%. Adjusted results included an unfavorable $0.11-per-share effect related to acquired in-process research and development and milestones expense.

Investing.com separately reported that adjusted EPS of $3.82 exceeded the analyst estimate of $3.74 by $0.08, while revenue of $17.4 billion was above the $17.36 billion consensus estimate. It also noted that AbbVie's $13.95-$13.99 full-year adjusted EPS guidance ranged from the $13.95 analyst consensus estimate to above it.

Skyrizi and Rinvoq drive immunology growth

AbbVie's global immunology portfolio generated $9.165 billion in third-quarter net revenue, an increase of 16.3% on a reported basis and 16.6% operationally. Skyrizi revenue reached $5.776 billion, up 22.7% reported and 22.9% operational, while Rinvoq revenue was $2.706 billion, up 23.9% reported and 24.3% operational.

By comparison, global Humira revenue declined 31.2% on a reported basis and 30.6% operationally to $683 million. The figures show sharply different third-quarter sales trends within AbbVie's immunology portfolio, although the reporting does not provide a broader measure of future adoption or demand.

Neuroscience offsets lower aesthetics revenue

Global neuroscience net revenue rose 19.4% on a reported basis and 19.5% operationally to $3.389 billion. Vraylar generated $1.068 billion, Botox Therapeutic $1.080 billion, Ubrelvy and Qulipta together $847 million, and Vyalev $286 million.

The oncology portfolio produced $1.696 billion in revenue, up 0.8% reported and 0.9% operational. Venclexta revenue was $803 million, Imbruvica was $522 million and Elahere was $224 million.

Aesthetics was the only portfolio reported as declining. Global net revenue fell 1.4% on a reported basis and 1.8% operationally to $1.176 billion, including $669 million from Botox Cosmetic and $222 million from Juvederm.

Apogee acquisition completed

AbbVie also said it had completed its acquisition of Apogee Therapeutics, which it described as deepening its immunology pipeline. The reviewed announcement does not state the cash consideration or other financial terms of the completed transaction, so the cash payer, recipient and transfer mechanics cannot be established from the available evidence.

Dividend and guidance milestones

AbbVie's first announced dividend payment under the 2027 increase is due in February 2027. The company also raised its 2026 adjusted diluted EPS guidance for the second time in the year, according to its results announcement. Future disclosure of revenue by portfolio, product and guidance will provide the next measurable test of the sales trends and outlook reported on October 30, 2026.